

Supplementary Table 2. Baseline characteristics of GTB patients who received ATT and who spontaneously conceived in the included studies

| Characteristic | Al Eryani et al. [19] (2015) | Bapna et al. [20] (2005) | Chatterjee et al. [9] (2020) | Jindal [21] (2006) | Jindal et al. [22] (2010) | Jindal et al. [23] (2012) | Kamal et al. [24] (2020) | Kulshreshta et al. [25] (2011) | Kriplani et al. [46] (2017) | Lin et al. [10] (2019) | Mondal and Dutta [26] (2009) | Naredi [27] (2014) | Sharma et al. [28] (2016) | Sharma et al. [29] (2016) | Tripathy and Tripathy [47] (2002) | Yue et al. [30] (2019) | Pooled average (95% CI), I ² (P-value) |
|--|------------------------------|--------------------------|------------------------------|--------------------|---------------------------|---------------------------------|--------------------------|--------------------------------|-------------------------------|------------------------|------------------------------|--------------------|---------------------------|---------------------------|-----------------------------------|------------------------|---|
| Length of study (yr) | 2 | 2 | 3 | 3 | 2 | 4 | 3 | 3 | 1 | 7 | 10 | 1 | 2 | 1 | 13 | 10 | 1 to 10 |
| Number of patients | 47 | 58 | 165 | 150 | 89 | 169 | 32 | 118 | 50 | 171 | 68 | 265 | 50 | 175 | 97 | 46 | 1,750 |
| Age (yr) | 28.06± 2.33 | 31 (22 to 40) | 29.27± 3.74 | 32.4±8.3 | NS | 32 (20 to 40) | 22 to 39 | 20 to 39 | 28.92± 3.88 | NS | NS | 28.8±2.2 | 21 to 37 | 28.3±4.6 | NS | NS | 29.2 (27.0 to 31.3), 0.0 (0.999) |
| Type of infertility | | | | | | | | | | | | | | | | | |
| Primary | 26 (55.7) | NS | NS | 105 (70.0) | NS | 131 (77.5) | 19 (59.3) | 83 (70.4) | 32 (64.0) | NS | NS | 219 (82.6) | 33 (66.0) | 130 (74.3) | 79 (81.4) | 43 (93.5) | 74.3 (64.8 to 83.8), 73 (<0.00001) |
| Secondary | 21 (44.3) | NS | NS | 45 (30.0) | NS | 38 (22.5) | 13 (40.7) | 35 (29.6) | 18 (36.0) | NS | NS | 46 (17.4) | 17 (34.0) | 45 (25.7) | 18 (18.6) | 3 (6.5) | 26.2 (20.5 to 32.0), 76 (<0.00001) |
| Duration of infertility (yr) | NS | 7 (1 to 23) | NS | NS | NS | 4 (1 to 18) | 6 to 10 | NS | 5.6±4.3 | NS | NS | 3.4±0.8 | 2 to 14 | NS | >5 | NS | 4.3 (3.0 to 5.7), 24 (0.257) |
| Imaging findings suggestive to FG TB (no. positive/tested) | | | | | | | | | | | | | | | | | |
| Normal ovary, tube, uterus | 28/47 (59.6) | 0/58 (0.0) | 0/165 (0.0) | 8/70 (11.4) | 7/89 (7.9) | 169/169 (100.0) ^b | 2/32 (6.3) | 31/118 (26.3) | 50/50 (100.0) ^b | 7/171 (4.1) | NS | NS | 2/50 (4.0) | 7/175 (4.0) | 27/73 (36.9) | 0/46 (0.0) | 12.1 (8.7 to 15.5), 96 (<0.00001) |
| Tuberculous tubal aetiology ^a | 19/47 (40.4) | 58/58 (100.0) | 165/165 (100.0) | 62/70 (88.6) | 81/89 (91.0) | 0/169 (0.0) ^b | 30/32 (93.7) | 87/118 (73.7) | 0/50 (0.0) ^b | 164/171 (95.9) | 27/65 (41.5) | NS | 48/50 (96.0) | 168/175 (96.0) | 46/73 (63.1) | 46/46 (100.0) | 66.1 (57.5 to 74.7), 99 (<0.00001) |
| Tubal blockage | 4/47 (8.5) | 33/58 (64.7) | 69/165 (41.8) | 25/70 (39.7) | NS | 0/169 (0.0) ^b | 10/32 (31.3) | 69/118 (58.6) | 0/50 (0.0) ^b | 164/171 (95.9) | 6/38 (15.8) | NS | 34/50 (68.0) | 48/107 (44.9) | 46/73 (63.1) | NS | 16.6 (13.7 to 19.5), 97 (<0.00001) |
| Coiled, kinked, beaded tube | 3/47 (6.4) | NS | 62/165 (37.6) | NS | NS | 0/169 (0.0) ^b | 7/32 (21.9) | 11/118 (9.3) | 0/50 (0.0) ^b | NS | 18/65 (27.7) | NS | 6/50 (12.0) | 26/175 (14.8) | 32/73 (43.8) | NS | 12.9 (8.8 to 17.1), 94 (<0.00001) |

Supplementary Table 2. Baseline characteristics of GTB patients who received ATT and who spontaneously conceived in the included studies (Continued)

| Characteristic | Al Eryani et al. [19] (2015) | Bapna et al. [20] (2005) | Chatterjee et al. [9] (2020) | Jindal [21] (2006) | Jindal et al. [22] (2010) | Jindal et al. [23] (2012) | Kamal et al. [24] (2020) | Kulshreshta et al. [25] (2011) | Kriplani et al. [46] (2017) | Lin et al. [10] (2019) | Mondal and Dutta [26] (2009) | Naredi [27] (2014) | Sharma et al. [28] (2016) | Sharma et al. [29] (2016) | Tripathy and Tripathy [47] (2002) | Yue et al. [30] (2019) | Pooled average (95% CI), I ² (P-value) |
|--|------------------------------|--------------------------|------------------------------|--------------------|---------------------------|---------------------------|--------------------------|--------------------------------|-----------------------------|------------------------|------------------------------|--------------------|---------------------------|---------------------------|-----------------------------------|------------------------|---|
| Hydrosalpinx | 0/47 (0.0) | 14/58 (24.1) | NS | NS | NS | 0/169 (0.0) ^b | 8/32 (25.0) | 23/118 (19.49) | 0/50 (0.0) ^b | NS | 4/38 (10.5) | NS | 16/50 (32.0) | 24/175 (13.7) | 32/73 (43.8) | 19/46 (41.3) | 8.9 (5.8 to 12.1), 92 (<0.00001) |
| Extravasation of fallopian tube | 1/47 (2.1) | NS | 34/165 (20.6) | 13/70 (20.6) | NS | 0/169 (0.0) ^b | NS | 14/118 (11.9) | 0/50 (0.0) ^b | NS | NS | NS | NS | NS | NS | NS | 4.1 (1.6 to 6.7), 91 (<0.00001) |
| Presence of nodules or tubercles | NS | 22/58 (37.9) | NS | 15/70 (21.4) | NS | 0/169 (0.0) ^b | NS | NS | 0/50 (0.0) ^b | NS | 18/65 (27.7) | NS | 27/50 (54.0) | 64/175 (36.6) | NS | NS | 16.6 (11.3 to 21.9), 96 (<0.00001) |
| Uterine abnormalities (including tuberculous inflammation) | NS | 23/58 (39.7) | NS | 28/51 (54.9) | 45/89 (50.7) | 0/169 (0.0) ^b | 18/32 (56.3) | 74/118 (62.7) | 0/50 (0.0) ^b | 0/171 (0.0) | 38/68 (55.9) | NS | NS | 110/175 (62.9) | NS | NS | 14.0 (10.2 to 17.9), 97 (0.0021) |
| Intrauterine synechia | NS | 20/58 (34.5) | NS | NS | NS | 0/169 (0.0) ^b | 18/32 (56.3) | NS | 0/50 (0.0) ^b | 0/171 (0.0) | 2/38 (5.3) | NS | NS | 59/175 (33.7) | NS | NS | 2.4 (0.6 to 4.3), 94 (<0.00001) |
| Endometrial atrophy | NS | NS | NS | NS | NS | 0/169 (0.0) ^b | NS | NS | 0/50 (0.0) ^b | 0/171 (0.0) | 3/68 (4.4) | NS | NS | NS | 52/92 (56.6) | NS | 0.8 (0.0 to 2.3), 93 (<0.00001) |
| Presence of nodules or tubercles or tuberculous inflammation | NS | 10/58 (17.2) | NS | 7/51 (13.7) | NS | 0/169 (0.0) ^b | NS | NS | 0/50 (0.0) ^b | 0/171 (0.0) | 38/68 (55.9) | NS | NS | 25/175 (14.3) | NS | NS | 2.2 (0.6 to 3.9), 92 (<0.00001) |
| Mild to moderate pelvic adhesions | NS | 21/58 (36.2) | NS | 37/70 (58.7) | NS | 0/169 (0.0) ^b | 18/32 (56.3) | NS | 0/50 (0.0) ^b | NS | 12/65 (18.5) | NS | 11/50 (22.0) | 55/175 (31.4) | NS | 45/46 (97.8) | 17.9 (12.6 to 23.2), 96 (<0.00001) |
| Frozen pelvis | NS | 10/58 (17.2) | NS | NS | NS | 0/169 (0.0) ^b | 7/32 (21.9) | 39/118 (19.9) | 0/50 (0.0) ^b | NS | 0/38 (0.0) | NS | 10/50 (20.0) | 38/175 (21.7) | NS | NS | 5.4 (2.9 to 8.0), 92 (<0.00001) |

Supplementary Table 2. Baseline characteristics of GTB patients who received ATT and who spontaneously conceived in the included studies (Continued)

| Characteristic | Al Eryani et al. [19] (2015) | Bapna et al. [20] (2005) | Chatterjee et al. [9] (2020) | Jindal [21] (2006) | Jindal et al. [22] (2010) | Jindal et al. [23] (2012) | Kamal et al. [24] (2020) | Kulshreshta et al. [25] (2011) | Kriplani et al. [46] (2017) | Lin et al. [10] (2019) | Mondal and Dutta [26] (2009) | Naredi [27] (2014) | Sharma et al. [28] (2016) | Sharma et al. [29] (2016) | Tripathy and Tripathy [47] (2002) | Yue et al. [30] (2019) | Pooled average (95% CI), I ² (P-value) |
|---|------------------------------|--------------------------|------------------------------|--------------------|---------------------------|-----------------------------|--------------------------|--------------------------------|-----------------------------|------------------------|------------------------------|--------------------|---------------------------|---------------------------|-----------------------------------|------------------------|---|
| Corrective surgery | | | | | | | | | | | | | | | | | |
| Yes | 0 (0.0) | 21 (36.2) | 100 (60.6) | 62 (41.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 56 (47.5) | 0 (0.0) | 0 (0.0) | 18 (26.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 1.1 (0.3 to 2.0), 95 (<0.00001) |
| Tuboplasty | 0 (0.0) | NS | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 2 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | NE |
| Salpingotomy | 0 (0.0) | NS | 100 (60.6) | NS | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 7 (10.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0.3 (0.0 to 0.8), 90 (<0.00001) |
| Salpingectomy | 0 (0.0) | NS | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 9 (13.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 27 (58.7) | 0.1 (0.0 to 0.4), 67 (0.0003) |
| Salpingotomy or salpingectomy | 0 (0.0) | NS | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 16 (23.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0.1 (0.0 to 0.3), 32 (0.134) |
| Salpingo-oophorectomy | 0 (0.0) | NS | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 13 (19.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0.1 (0.0 to 0.2), 17 (0.281) |
| Hysteroscopic adhesiolysis | 0 (0.0) | 20 (24.4) | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 2 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0.1 (0.0 to 0.3), 46 (0.036) |
| Pelvic adhesiolysis and fimbrioplasty | 0 (0.0) | 1 (1.2) | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | NS | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NS | NE |
| No | 47 (100.0) | NS | 65 (39.4) | 88 (58.7) | 89 (100.0) | 169 (100.0) | 32 (100.0) | 62 (52.5) | 169 (100.0) | 171 (100.0) | 50 (73.5) | 265 (100.0) | 50 (100.0) | 175 (100.0) | 97 (100.0) | NS | 98.7 (79.5 to 117.8), 95 (<0.00001) |
| Positive diagnosis of TB (+TB/no. of patients tested) | | | | | | | | | | | | | | | | | |
| Hysterosalpingography | 8/47 (17.1) | 0/0 | 165/165 (100.0) | 84/118 (71.2) | 0/0 | 0/169 (0.0) ^b | 0/0 | 118/118 (100.0) | 0/50 (0.0) ^b | 164/171 (95.9) | 13/38 (34.2) | 227/227 (100.0) | 0/0 | 79/107 (73.9) | 35/35 (100.0) | 0/0 | 57.4 (48.3 to 66.5), 99 (<0.00001) |

Supplementary Table 2. Baseline characteristics of GTB patients who received ATT and who spontaneously conceived in the included studies (Continued)

| Characteristic | Al Eryani et al. [19] (2015) | Bapna et al. [20] (2005) | Chatterjee et al. [9] (2020) | Jindal [21] (2006) | Jindal et al. [22] (2010) | Jindal et al. [23] (2012) | Kamal et al. [24] (2020) | Kulshreshta et al. [25] (2011) | Kriplani et al. [46] (2017) | Lin et al. [10] (2019) | Mondal and Dutta [26] (2009) | Naredi [27] (2014) | Sharma et al. [28] (2016) | Sharma et al. [29] (2016) | Tripathy and Tripathy [47] (2002) | Yue et al. [30] (2019) | Pooled average (95% CI), I ² (P-value) | |
|----------------------------------|---|--------------------------|------------------------------|---|---|---|---------------------------------|---|-------------------------------|------------------------|------------------------------|---|---|---|---|---|---|---|
| Laparoscopy | 19/33 (57.6) | 58/58 (100.0) | 165/165 (100.0) | 62/70 (88.6) | 81/89 (91.0) | 0/169 (0.0) ^b | 30/32 (94.0) | 87/118 (73.7) | 0/0 | 0/0 | 0/0 | 0/0 | 43/50 (86.0) | 169/175 (96.6) | 73/73 (100.0) | 46/46 (100.0) | 82.0 (45.4 to 118.7), 99 (<0.00001) | |
| Hysteroscopy | 0/0 | 25/58 (34.5) | 0/0 (0.0) | 28/51 (18.7) | 45/89 (50.7) | 0/169 (0.0) ^b | 18/32 (56.3) | 74/118 (62.7) | 0/0 | 0/0 | 0/0 | 0/0 | 11/50 (22.0) | 110/175 (62.9) | 0/0 | NS | 43.7 (17.9 to 69.4), 98 (<0.00001) | |
| USG | 0/0 | 0/0 | 0/0 | 49/139 (35.2) | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 16/27 (59.3) | 217/217 (100.0) | 0/0 | 93/175 (53.1) | 0/0 | 0/0 | 61.8 (32.2 to 91.5), 95 (<0.00001) | |
| Histopathology or AFB microscopy | 34/47 (72.3) | 16/41 (39.0) | 0/0 (0.0) | 30/66 (45.5) | 12/89 (13.5) | 0/169 (0.0) ^b | 3/32 (9.4) | 7/118 (5.9) | 0/50 (0.0) ^b | 171/171 (100.0) | 4/68 (5.9) | 0/0 | 7/50 (14.0) | 52/175 (29.7) | 97/97 (100.0) | 13/46 (28.3) | 28.7 (20.7 to 36.8), 97 (<0.00001) | |
| Culture | 5/19 (26.3) | 0/0 | 0/0 (0.0) | 7/50 (14.0) | 0/0 | 0/0 | 0/0 | 4/118 (3.4) | 0/50 (0.0) ^b | 0/0 | 37/68 (54.4) | 0/0 | 0/0 | 19/175 (10.9) | 0/0 | 0/0 | 15.6 (3.5 to 27.8), 93 (<0.00001) | |
| PCR | 15/34 (44.1) | 0/0 | 165/165 (100.0) | 0/0 | 52/89 (58.4) | 169/169 (100.0) ^b | 19/32 (59.4) | 81/118 (68.6) | 50/50 (100.0) ^b | 171/171 (100.0) | 27/68 (39.7) | 0/0 | 50/50 (100.0) | 166/175 (94.9) | 0/0 | 0/0 | 78.8 (68.5 to 88.6), 87 (<0.00001) | |
| Others (ELISA/ESR/mantoux) | 26/47 (55.3) | 0/0 | 0/0 | 38/42 (90.5) | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 265/265 (100.0) | 0/0 | 0/0 | 0/0 | 0/0 | 58.7 (34.0 to 83.7), 84 (0.0002) | |
| History of TB | 9 (19.1) | NS | NS | 0 (0.0) | NS | 0 (0.0) | 4 (12.5) | 5 (2.6) | 0 (0.0) | 61 (35.7) | NS | 0 (0.0) | NS | NS | NS | NS | 8.1 (0.0 to 18.1), 91 (<0.00001) | |
| ATT duration (months) | 6 | 6 to 12 | 6 | 6 | 6 | 6 | 6 to 9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 or 9 | 6 or 9 | 6 | 6 to 12 |
| ATT drugs | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | NS | NS | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | INH+RMP+ EMB+PZA 6 months | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | NS | NS | NS | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months | INH+RMP+ EMB+PZA 2 months; INH+RMP 4 months or 7 months |

Supplementary Table 2. Baseline characteristics of GTB patients who received ATT and who spontaneously conceived in the included studies (Continued)

| Characteristic | Al Eryani et al. [19] (2015) | Bapna et al. [20] (2005) | Chatterjee et al. [9] (2020) | Jindal [21] (2006) | Jindal et al. [22] (2010) | Jindal et al. [23] (2012) | Kamal et al. [24] (2020) | Kulshreshta et al. [25] (2011) | Kriplani et al. [46] (2017) | Lin et al. [10] (2019) | Mondal and Dutta [26] (2009) | Naredi [27] (2014) | Sharma et al. [28] (2016) | Sharma et al. [29] (2016) | Tripathy and Tripathy [47] (2002) | Yue et al. [30] (2019) | Pooled average (95% CI), I ² (P-value) |
|----------------|------------------------------|--------------------------|------------------------------|--------------------|--|--|--------------------------|--------------------------------|-----------------------------|------------------------|------------------------------|--|---------------------------|--|-----------------------------------|------------------------|---|
| ATT drugs dose | NS | NS | NS | NS | INH 300 mg, RMP 450-600 mg, EMB 800-1,200 mg, PZA 1,200-1,500 mg | INH 300 mg, RMP 450-600 mg, EMB 800-1,200 mg, PZA 1,200-1,500 mg | NS | NS | NS | NS | NS | INH 300 mg, RMP 450-600 mg, EMB 800-1,200 mg, PZA 1,200-1,500 mg | NS | INH 300 mg, RMP 450-600 mg, EMB 800-1,200 mg, PZA 1,200-1,500 mg | NS | NS | |

GTB, genital tuberculosis; ATT, antitubercular therapy; CI, confidence interval; NS, not stated; FG TB, female genital tuberculosis; NE, not estimable; TB, tuberculosis; USG, ultrasound sonography; AFB, acid-fast bacilli; PCR, polymerase chain reaction; ELISA, enzyme linked immunosorbent assay; ESR, erythrocyte sedimentation rate; INH, isoniazid; RMP, rifampicin; EMB, ethambutol; PZA, pyrazinamid.

^aIncluding definitive (multiple granuloma, exudates, loculated fluid, adhesion, hydrosalpinges, and beaded tubes) and probable (signs of chronic inflammation, patent tubes with congestion, small scattered granulomas, fimbrial agglutination and phimosis, tubal sacculation, mild adhesion, and fluid in pouch of Douglas) diagnosis.

^bLatent or subclinical tuberculosis: no evidence of tubal or endometrial damage while the PCR test was positive for mycobacterium tuberculosis.